What the Evidence Says About Cannabis for Inflammatory Bowel Disease | Research

The takeaway

A review found that while the endocannabinoid system plays a key role in IBD pathogenesis and animal models show therapeutic potential, human evidence is limited to symptomatic relief without proven anti-inflammatory effects.

People with inflammatory bowel disease interested in what evidence exists for cannabis as a treatment option.

Symptomatic relief observed in patients but objective anti-inflammatory effects not yet demonstrated

What the researchers found

This review examined the evidence for cannabis as a treatment for inflammatory bowel disease (IBD), covering endocannabinoid system science, animal models, epidemiological data, and human studies.

Animal research showed that modulating the endocannabinoid system had therapeutic effects in mouse colitis models. Epidemiological data suggested cannabis use is common among IBD patients, with many reporting symptom improvement.

However, human therapy studies had not yet demonstrated objective anti-inflammatory effects. The available evidence suggested cannabis may provide symptomatic relief (pain, appetite, nausea) without addressing the underlying intestinal inflammation. The review called for large, placebo-controlled trials using objective measures like inflammatory markers, biopsies, and endoscopy.

Why it matters

Many IBD patients use cannabis, and some report significant symptom relief. This review clarifies an important distinction: symptomatic improvement does not necessarily mean the underlying disease is being treated. Without evidence of anti-inflammatory effects, cannabis may mask symptoms while inflammation continues.

The numbers in context

No specific trial results were presented. The review synthesized findings across preclinical models (showing endocannabinoid system involvement in IBD pathogenesis), surveys (showing high cannabis use among IBD patients), and limited clinical data.

How the study worked

This was a comprehensive review article in a gastroenterology journal, examining preclinical evidence, epidemiological surveys, and the limited clinical trial data on cannabis and IBD. The review also addressed safety considerations and research gaps.

What this study cannot tell us

The review highlighted the absence of large, double-blind, randomized controlled trials. Existing human data relied on subjective symptom reports rather than objective inflammatory measures. The review could not determine optimal dosing, formulation, or route of administration for potential therapeutic use.

How to read the evidence

This is a comprehensive review drawing on preclinical evidence, epidemiological data, and limited human studies. The overall evidence for cannabis in IBD remains preliminary due to a lack of controlled trials.

When this study was published

Published in 2016. Several clinical trials on cannabis and IBD have been conducted since, though evidence of anti-inflammatory effects in humans remains limited.

The bigger picture

The gap between patient-reported benefits and objective clinical evidence reflects a broader challenge in cannabis research. IBD patients often turn to cannabis when standard treatments fail, but without rigorous clinical trials, the risk-benefit ratio remains unclear.

Questions still open

Will controlled trials show that cannabis reduces intestinal inflammation, or only symptoms? What cannabinoid formulations and delivery methods might be most effective for IBD?

Common questions

Can cannabis treat inflammatory bowel disease?

Current evidence suggests cannabis may relieve IBD symptoms like pain, nausea, and appetite loss, but it has not been shown to reduce the underlying intestinal inflammation. This is an important distinction because untreated inflammation can lead to complications even when symptoms improve.

Is it safe for IBD patients to use cannabis?

The review noted safety concerns including potential drug interactions, cognitive effects, and the risk of masking symptoms while inflammation persists. The authors recommended reserving cannabis for patients with severe IBD refractory to standard treatments.

Read the original research

Therapeutic Use of Cannabis in Inflammatory Bowel Disease.

Gastroenterology & hepatology, 12(11), 668-679

View on PubMed ↗

Citation

Ahmed, Waseem; Katz, Seymour. (2016). Therapeutic Use of Cannabis in Inflammatory Bowel Disease.. Gastroenterology & hepatology, 12(11), 668-679.